# Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma

> **NCT01454076** · PHASE1 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 112 (actual)

## Conditions studied

- Nonhematologic Malignancies
- Lymphoma

## Interventions

- **DRUG:** Ixazomib 2.5 mg
- **DRUG:** Ixazomib 4 mg Capsule A
- **DRUG:** Ixazomib 4 mg Capsule B
- **DRUG:** Ketoconazole
- **DRUG:** Rifampin
- **DRUG:** Clarithromycin
- **DRUG:** Ixazomib 4 mg Capsule B

## Key facts

- **NCT ID:** NCT01454076
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11-10
- **Primary completion:** 2015-04-01
- **Final completion:** 2016-06-16
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2017-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01454076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01454076, "Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01454076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*